Haemonetics Corporation and SABM Announce Research Grant
Published: May 29, 2013
BRAINTREE, Mass., May 29, 2013 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced today that it is sponsoring a Patient Blood Management grant through the Society for the Advancement of Blood Management (SABM), one of its leading partnerships. The SABM-Haemonetics Research Starter Grant is intended to advance the field of patient blood management by supporting a young investigator who plans to study methods of blood conservation. This one-year grant provides starter funding to further scientific inquiry and clinical knowledge in the field of patient blood management.
"We are very pleased to sponsor the SABM-Haemonetics Research Starter Grant with SABM," said Brian Concannon, President and CEO. "As THE Blood Management Company we are committed to transforming and improving the practice of blood management globally. Supporting this vital research is an important part of our mission."
It is expected that the funded study will generate results that can be used as pilot data or preliminary findings to support future grant applications focused on methods to improve blood management and to promote blood conservation. Areas of research that will be considered include: Process Improvement and Scientific Inquiry. Applications are due by August 1, 2013. The awardee will be formally recognized at the 2013 SABM Annual Meeting being held on September 19-21 in Los Angeles, California. Funding will begin October 1, 2013.
The Society for the Advancement of Blood Management (SABM) defines its mission as the improvement of health outcomes by advancing comprehensive patient blood management practices, promoting innovative research, and providing quality professional and public education.
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, IT products, and consulting services deliver a suite of business solutions to help our customers improve patient care and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our website at www.haemonetics.com.
Gerry Gould, VP-Investor Relations
Tel. (781) 356-9402
Alt. (781) 356-9613
Help employers find you! Check out all the jobs and post your resume.